Company intelligence / Profile preview
DNX Biopharmaceuticals
San Diego, California, USAdnxbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
DNX Biopharmaceuticals is developing long-acting, non-immunogenic therapeutic proteins for inflammatory and oncologic disorders. Several programs are in preclinical stages, including candidates designed as immune checkpoint inhibitors for cancer immunotherapy, with prior assets entering nonclinical or discontinued stages in other indications. The company has a strategic partnership with Johnson & Johnson’s Lung Cancer Initiative[1][3][5][6].
- Therapeutic areas
- OncologyRheumatologyOphthalmologyImmunology
- Modalities
- ProteinBiologicMonoclonal antibodyRecombinant proteinAntibodyImmune checkpoint inhibitor
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
XL-proteinJohnson & Johnson Innovation – JLABSLung Cancer Initiative at Johnson & Johnson
Beyond the preview
Go deeper on DNX Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNX Biopharmaceuticals.